Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

OBJECTIVES: Primary * Determine the 2-year progression-free survival of patients with advanced mantle cell lymphoma or indolent lymphoma treated with bortezomib, cladribine, and rituximab. Secondary * Determine the 2-year overall survival of patients treated with this regimen. * Determine the complete response and overall response rate in patients treated with this regimen. * Describe the long- and short-term toxicity of this regimen in these patients. * Determine the prognostic importance of Aurora kinase A in patients treated with this regimen. * Determine the cytokine profiles for each lymphoma subtype and how they change with this regimen. * Evaluate the prognostic importance of major carcinogenic pathways using tissue microarray. OUTLINE: Patients receive bortezomib IV on days 1 and 4, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and after course 1 for cytokine profile studies. Previously collected tissue samples are obtained for analysis of Aurora kinase A and B, Ki-67, cyclin D, Bcl-2, phosphor-HisH3, c-Met, and VEGF expression by using tissue microarray (IHC staining), reverse transcriptase-PCR, and/or western blotting. After completion of study therapy, patients are followed up every 3 months for 2 years.